| Share


MELBOURNE, March 15, 2019: Hemideina, a hearing solutions company focussed on the development and commercialisation of the Hera Wireless Implant, announced today that it was awarded an $800,000 grant from Accelerating Commercialisation, under the Australian Government’s Entrepreneurs’ Programme.


The funding will enable Hemideina to strengthen its Intellectual Property portfolio, plan market access pathways, and trial the Hera Wireless Implant device for safety and efficacy. 


Dr Elizabeth Williams, CEO and Co-Founder of Hemideina said: “The Accelerating Commercialisation grants are very competitive. Receiving the grant is a significant milestone for Hemideina, and further validates our design capabilities and capacity to disrupt the established hearing implant market with a second-generation alternative.”


Dr Kate Lomas, Co-Founder and Chief Scientific Officer, describing the Company’s patented acoustic technology, said: “We have an opportunity to bring this technology to the market, which should seed further Australian-based technology innovations for people with unmet needs in hearing solutions.” 


Andrew Maxwell, Chairman of the Board, said: “The Accelerating Commercialisation program is critical to the success of Australia’s well-respected innovation eco-system. Companies like Hemideina, undertaking early commercialisation of essential products for the global human health sector, urge all levels of government to continue to champion research and development incentives of this kind. 


“Accelerating Commercialisation, coupled with the R&D Tax Incentive, are vital for Australia to build companies that will create a sustainable industry and jobs-based innovation in human healthcare. Together, we can be the architects of more Australian success stories by driving competitiveness and economic returns and accelerating sustainable progress with these incentives.” 








About Hemideina


Founded in 2017 with a mission to revolutionise hearing for the profoundly deaf, Hemideina takes inspiration from biological systems to deliver solutions in human hearing. Hemideina’s Hera Wireless Implant is based on the company’s proprietary signal processing technology and is set to disrupt the hearing implant market currently worth $1.8bn. 


Media contact:

Georgie Morell
Morell & Co
0438 008 383


For more information, please visit www.hemideina.com.